Drug Approval | April 14, 2026
CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Panacea Biotec receives LoA from CMSS
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Subscribe To Our Newsletter & Stay Updated
